Resignation of Director & CRO Dr. Graham Melrose
Released
Released
Announcement PDF
Resignation of Director & Chief Research Officer
Dr. Graham Melrose
Sydney Australia, 3 July 2020: Recce Pharmaceuticals Ltd (ASX: RCE) (Company),
the Company developing new classes of broad-spectrum synthetic antibiotics,
announces the completion of Dr. Graham Melrose’s executive service agreement as
Chief Research Officer and his resignation as Executive Director from the Board.
A
pioneer in
synthetic
antibiotic
development,
Dr Melrose
founded
Recce
Pharmaceuticals Ltd in 2008, later co-inventing RECCE® antibiotics with Executive
Director Michele Dilizia. He concludes a career of significant contributions to the world of
Infectious Diseases, advancing a number of transformative medical technologies,
including some eight years as former Executive Director and Head of Research at
Johnson & Johnson (Aus).
Dr Melrose said: “Recce was formed with a mission to address the global health threat
of antibiotic resistance and I feel we have made generationally significant in-roads in
that endeavour. The Company is now well setup to pursue its objectives, with expanding
indications across a range of significant and unmet infectious diseases. I expect
subsequent advances to reflect this and thank all for the support I have received.”
Dr. John Prendergast, Non-Executive Chairman, added, “Recce is truly indebted to Dr.
Melrose for his innovation, dedication and passion in creating our products and
participating in their development. The foundation from Graham’s work allows us to
move forward with confidence as the Company looks to achieve significant clinical and
business milestones. For this we say emphatically, Thank You!”
The Company thanks Dr. Melrose for his outstanding service and wishes him the very
best.
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialization
of new classes of synthetic antibiotics with broad spectrum activity designed to address the urgent
global health problem of antibiotic resistant superbugs.
Recce antibiotics are unique – their potency does not diminish even with repeated use, which is
a common failure associated with existing antibiotic use and the resulting emergence of resistant
superbugs.
Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been
developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus
bacteria – including their superbug forms.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the
Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus
10 years of market exclusivity post approval.
Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies
targeting synergistic, unmet medical needs.
Share your feedback
Discover